CLEC5A and systemic inflammatory response syndrome: CLEC5A has been suggested as a therapeutic target not only in the context of infection but also in inflammatory disorders (mostly based on the enhanced CLEC5A expression in these entities), for instance, in autoimmune-mediated skeletal disorders like rheumatoid arthritis or in systemic inflammatory response syndrome [3, 4].